【CLAIMS】

1. A compound represented by the following Chemical Formula 2 or a pharmaceutically acceptable salt thereof:

[Chemical Formula 2]



in the Chemical Formula 2,

X_1 is F;

X_2 is hydrogen or F;

R_1 is methyl; and

R_2 is methoxy, ethoxy, methyl or ethyl.

2. The compound, or the pharmaceutically acceptable salt thereof of claim 1, wherein R_2 is methoxy or methyl.

3. The compound, or the pharmaceutically acceptable salt thereof of claim 1, wherein R_1 is methyl, and

R_2 is methoxy or methyl.

4. The compound, or the pharmaceutically acceptable salt thereof of claim 1,

wherein

X_1 is F;

X_2 is F;

R_1 is methyl; and

R_2 is methoxy or methyl.

5. The compound, or the pharmaceutically acceptable salt thereof of claim 1,

wherein

X_1 is F;

X_2 is hydrogen;

R_1 is methyl; and

R_2 is methoxy or methyl.

6. The compound, or the pharmaceutically acceptable salt thereof of claim 1,

wherein

X_1 is F;

X_2 is hydrogen or F;

R_1 is methyl; and

R_2 is methoxy.

7. The compound, or the pharmaceutically acceptable salt thereof of claim 1, wherein

X_1 is F;

X_2 is hydrogen or F;

R_1 is methyl; and

R_2 is methyl.

8. The compound, or the pharmaceutically acceptable salt thereof of claim 1, wherein the compound represented by Chemical Formula 2 is any one selected from the group consisting of the following compounds:

1-(5-(2-fluorophenyl)-4-methoxy-1-((6-methoxypyridin-3-yl)sulfonyl)-1*H*-pyrrol-3-yl)-*N*-methylmethanamine;

1-(5-(2,4-difluorophenyl)-4-methoxy-1-((6-methoxypyridin-3-yl)sulfonyl)-1*H*-pyrrol-3-yl)-*N*-methylmethanamine;

1-(5-(2,4-difluorophenyl)-4-methoxy-1-((6-methylpyridin-3-yl)sulfonyl)-1*H*-pyrrol-3-yl)-*N*-methylmethanamine; and

1-(5-(2-fluorophenyl)-4-methoxy-1-((6-methylpyridin-3-yl)sulfonyl)-1*H*-pyrrol-3-yl)-*N*-methylmethanamine.

9. A pharmaceutical composition for preventing or treating gastrointestinal ulcers, gastrointestinal inflammatory diseases, or gastric acid-related diseases, comprising the compound according to any one of claim 1 to 8 or the pharmaceutically acceptable salt thereof,

wherein the gastrointestinal ulcer, gastrointestinal inflammatory disease or gastric acid-related disease is any one or more selected from the group consisting of peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcer, acute stress ulcer, Zollinger-Ellison syndrome, Helicobacter pylori infection, gastritis, erosive esophagitis, non-erosive esophagitis, reflux esophagitis, inflammatory bowel disease, symptomatic gastroesophageal reflux disease (symptomatic GERD), functional dyspepsia, gastric cancer, gastric MALT lymphoma, hyperacidity, and upper gastrointestinal hemorrhage due to invasive stress.

10. Use of the compound according to any one of claim 1 to 8 or the pharmaceutically

acceptable salt thereof in the manufacture of a medicament for treatment of gastrointestinal ulcers, gastrointestinal inflammatory diseases or gastric acid-related diseases,

wherein the gastrointestinal ulcer, gastrointestinal inflammatory disease or gastric acid-related disease is any one or more selected from the group consisting of peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcer, acute stress ulcer, Zollinger-Ellison syndrome, Helicobacter pylori infection, gastritis, erosive esophagitis, non-erosive esophagitis, reflux esophagitis, inflammatory bowel disease, symptomatic gastroesophageal reflux disease (symptomatic GERD), functional dyspepsia, gastric cancer, gastric MALT lymphoma, hyperacidity, and upper gastrointestinal hemorrhage due to invasive stress.